The tool can help clinicians stratify patients into high-risk and low-risk categories. A team of investigators has developed a nomogram they say can help predict which patients with myasthenia gravis ...

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today ...

Results of Genoidentical Hemopoietic Stem Cell Transplantation With Reduced Intensity Conditioning for Acute Myelocytic Leukemia: Higher Doses of Stem Cells Infused Benefit Patients Receiving ...

A nomogram was developed to identify high-risk myasthenia gravis patients, focusing on those with bulbar weakness. Key risk factors include MGFA stage 3/4, thymoma presence, inability to lie flat, and ...

PSMA PET-based (PPP3) nomograms outperform conventional risk scoring in determining overall survival over 3, 5, and 7 years across the prostate cancer spectrum. Nomograms based on prostate-specific ...

More than 65,000 Americans are diagnosed annually with head and neck cancer, which most often occurs inside the mouth and throat. For patients who undergo surgery to treat this cancer, guidelines ...

Our aim was to develop a quantitative prediction tool for individual patient's 3-/5-year overall survival (OS) probability. We integrated established clinical and molecular risk factors into a ...

Please provide your email address to receive an email when new articles are posted on . Internally validated nomograms predicted the probability of early death and identified risk factors among ...

Ductal carcinoma in situ (DCIS) is a heterogeneous disease with multiple treatment options including breast-conserving surgery, the option of addition of radiation, and adjuvant endocrine therapy.